{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:33:59Z","timestamp":1793118839550,"version":"4.5.0"},"reference-count":112,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005677","name":"Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008129","name":"Helsinn","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018747","name":"SkylineDx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019944","name":"Sanofi-Aventis Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019944","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.esmoop.2022.100403","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T05:55:49Z","timestamp":1643349349000},"page":"100403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Managing hematological cancer patients during the COVID-19 pandemic: an\u00a0ESMO-EHA Interdisciplinary Expert Consensus"],"prefix":"10.1016","volume":"7","author":[{"given":"C.","family":"Buske","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Alvarez-Larr\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Apperley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Arcaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Besson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bullinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Giovanni Della Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"D\u2019Sa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.T.","family":"Eich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Fo\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ghia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.G.","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gribben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Hajek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Heuser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Kiesewetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Kiladjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.","family":"Passweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Peyvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Rea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-M.","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Robak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.","family":"San-Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"von Lilienfeld-Toal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Wendtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pentheroudakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Passamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2022.100403_bib1","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100403_bib2","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0140-6736(20)32656-8","article-title":"6-month consequences of COVID-19 in patients discharged from hospital: a cohort study","volume":"397","author":"Huang","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100403_bib3","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(20)31173-9","article-title":"COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study","volume":"395","author":"Lee","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100403_bib4","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","article-title":"Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study","volume":"7","author":"Passamonti","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.esmoop.2022.100403_bib5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13045-020-00970-7","article-title":"Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study","volume":"13","author":"Garcia-Suarez","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.esmoop.2022.100403_bib6","doi-asserted-by":"crossref","first-page":"5966","DOI":"10.1182\/bloodadvances.2020003170","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub","volume":"4","author":"Wood","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.esmoop.2022.100403_bib7","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood.2020008824","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.esmoop.2022.100403_bib8","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1182\/blood.2020008150","article-title":"Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set","volume":"136","author":"Chari","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.esmoop.2022.100403_bib9","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood.2020006965","article-title":"Outcomes of COVID-19 in patients with CLL: a multicenter international experience","volume":"136","author":"Mato","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.esmoop.2022.100403_bib10","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1097\/HS9.0000000000000538","article-title":"Risk factors and mortality of COVID-19 in patients with lymphoma: a multicenter study","volume":"5","author":"Regalado-Artamendi","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.esmoop.2022.100403_bib11","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2352-3026(20)30429-4","article-title":"Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study","volume":"8","author":"Sharma","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.esmoop.2022.100403_bib12","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bjh.17704","article-title":"COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies","volume":"195","author":"Passamonti","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.esmoop.2022.100403_bib13","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s10038-020-0808-9","article-title":"SARS-CoV-2 genomic variations associated with mortality rate of COVID-19","volume":"65","author":"Toyoshima","year":"2020","journal-title":"J\u00a0Hum Genet"},{"key":"10.1016\/j.esmoop.2022.100403_bib14","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/ajh.26284","article-title":"BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies","volume":"96","author":"Herzog Tzarfati","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.esmoop.2022.100403_bib15","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1016\/S2352-3026(21)00169-1","article-title":"Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study","volume":"8","author":"Maneikis","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.esmoop.2022.100403_bib16","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/bjh.17743","article-title":"Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients","volume":"195","author":"Benda","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.esmoop.2022.100403_bib17","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ccell.2021.07.012","article-title":"Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies","volume":"39","author":"Greenberger","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.esmoop.2022.100403_bib18","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.esmoop.2022.100403_bib19","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1038\/s41375-021-01270-w","article-title":"COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia","volume":"35","author":"Roeker","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.esmoop.2022.100403_bib20","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/bloodadvances.2021005094","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma","volume":"5","author":"Perry","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.esmoop.2022.100403_bib21","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.2021012443","article-title":"Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell directed therapies","volume":"138","author":"Ghione","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.esmoop.2022.100403_bib22","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S2352-3026(21)00199-X","article-title":"Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma","volume":"8","author":"Lim","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.esmoop.2022.100403_bib23","first-page":"715","article-title":"Humoral serologic response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies","volume":"107(3)","author":"Gurion","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.esmoop.2022.100403_bib24","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41408-021-00530-3","article-title":"The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment","volume":"11","author":"Terpos","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.esmoop.2022.100403_bib25","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ccell.2021.06.014","article-title":"Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma","volume":"39","author":"Van Oekelen","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.esmoop.2022.100403_bib26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-021-01090-6","article-title":"Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution","volume":"14","author":"Pimpinelli","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.esmoop.2022.100403_bib27","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3026(21)00110-1","article-title":"Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma","volume":"8","author":"Bird","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.esmoop.2022.100403_bib28","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/blood.2021011904","article-title":"Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose","volume":"137","author":"Terpos","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.esmoop.2022.100403_bib29","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13045-021-01130-1","article-title":"Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia","volume":"14","author":"Pimpinelli","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.esmoop.2022.100403_bib30","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1038\/s41375-021-01300-7","article-title":"Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms","volume":"35","author":"Harrington","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.esmoop.2022.100403_bib31","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/bjh.17568","article-title":"Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia","volume":"194","author":"Harrington","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.esmoop.2022.100403_bib32","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/bjh.17402","article-title":"Evidence of robust memory T-cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)","volume":"193","author":"Harrington","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.esmoop.2022.100403_bib33","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1016\/S2468-2667(20)30090-6","article-title":"Impact assessment of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study","volume":"5","author":"Cowling","year":"2020","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.esmoop.2022.100403_bib34","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/irv.12745","article-title":"Medical masks vs N95 respirators for preventing COVID-19 in healthcare workers: a systematic review and meta-analysis of randomized trials","volume":"14","author":"Bartoszko","year":"2020","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.esmoop.2022.100403_bib35","first-page":"107","article-title":"The role of community-wide wearing of face mask for control of coronavirus disease 2019 (COVID-19) epidemic due to SARS-CoV-2","volume":"81","author":"Cheng","year":"2020","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.esmoop.2022.100403_bib36","doi-asserted-by":"crossref","first-page":"m1923","DOI":"10.1136\/bmj.m1923","article-title":"Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: prospective cohort study","volume":"369","author":"Lewnard","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.esmoop.2022.100403_bib37","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.3201\/eid2608.201093","article-title":"Evaluating the effectiveness of social distancing interventions to delay or flatten the epidemic curve of coronavirus disease","volume":"26","author":"Matrajt","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.esmoop.2022.100403_bib38","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1017\/S0950268809991658","article-title":"Face masks to prevent transmission of influenza virus: a systematic review","volume":"138","author":"Cowling","year":"2010","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.esmoop.2022.100403_bib39","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41591-020-0843-2","article-title":"Respiratory virus shedding in exhaled breath and efficacy of face masks","volume":"26","author":"Leung","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2022.100403_bib40","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1111\/bjh.16818","article-title":"Successful prevention and screening strategies for COVID-19: focus on patients with haematologic diseases","volume":"190","author":"Cho","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.esmoop.2022.100403_bib41","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41591-020-0874-8","article-title":"Caring for patients with cancer in the COVID-19 era","volume":"26","author":"van de Haar","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2022.100403_bib42","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000508272","article-title":"Implications of SARS-CoV-2 infection and COVID-19 crisis on clinical cancer care: report of the University Cancer Center Hamburg","volume":"43","author":"Weisel","year":"2020","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.esmoop.2022.100403_bib43","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/j.1532-5415.2009.02402.x","article-title":"Effect of influenza vaccination of nursing home staff on mortality of residents: a cluster-randomized trial","volume":"57","author":"Lemaitre","year":"2009","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.esmoop.2022.100403_bib44","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100403_bib45","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100403_bib46","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100403_bib47","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood-2006-06-032284","article-title":"Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation","volume":"109","author":"Meisel","year":"2007","journal-title":"Blood"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2022.100403_bib48","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/irv.12084","article-title":"Influenza vaccination for immunocompromised patients: summary of a systematic review and meta-analysis. Influenza","volume":"7","author":"Beck","year":"2013","journal-title":"Other Respir Viruses"},{"key":"10.1016\/j.esmoop.2022.100403_bib49","first-page":"CD008983","article-title":"Influenza vaccines in immunosuppressed adults with cancer","volume":"2","author":"Bitterman","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.esmoop.2022.100403_bib50","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/S0140-6736(18)30631-7","article-title":"Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Winston","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100403_bib51","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/annonc\/mdy117","article-title":"Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)","volume":"29","author":"Rieger","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100403_bib52","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1016\/S1473-3099(18)30601-7","article-title":"Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Mikulska","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.esmoop.2022.100403_bib53","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S1473-3099(18)30600-5","article-title":"Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Cordonnier","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.esmoop.2022.100403_bib54","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejca.2021.01.033","article-title":"2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy","volume":"147","author":"Giesen","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2022.100403_bib55","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejca.2018.09.012","article-title":"Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events","volume":"104","author":"Wijn","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2022.100403_bib56","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.annonc.2020.03.290","article-title":"Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1","volume":"31","author":"Bayle","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100403_bib57","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1056\/NEJMc2105869","article-title":"Thrombotic thrombocytopenia after Ad26.COV2.S vaccination","volume":"384","author":"Muir","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100403_bib58","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1056\/NEJMc2106075","article-title":"Thrombotic thrombocytopenia after Ad26.COV2.S vaccination - response from the manufacturer","volume":"384","author":"Sadoff","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100403_bib59","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa2107051","article-title":"Adjunct immune globulin for vaccine-induced immune thrombotic thrombocytopenia","volume":"385","author":"Bourguignon","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100403_bib60","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100403_bib61","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1161\/CIRCULATIONAHA.121.055913","article-title":"Myocarditis after BNT162b2 and mRNA-1273 vaccination","volume":"144","author":"Larson","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.esmoop.2022.100403_bib62","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1056\/NEJMoa2008457","article-title":"Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility","volume":"382","author":"Arons","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100403_bib63","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ijid.2021.02.117","article-title":"Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted in an Italian Reference Hospital","volume":"105","author":"Mondi","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.esmoop.2022.100403_bib64","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.cell.2020.10.049","article-title":"Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer","volume":"183","author":"Avanzato","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.esmoop.2022.100403_bib65","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/infdis\/jiaa311","article-title":"Decreased B cells on admission associated with prolonged viral RNA shedding from the respiratory tract in coronavirus disease 2019: a case-control study","volume":"222","author":"Hao","year":"2020","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.esmoop.2022.100403_bib66","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41467-020-20568-4","article-title":"Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)","volume":"12","author":"van Kampen JJA","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2022.100403_bib67","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1002\/jmv.26896","article-title":"High performance of a novel antigen detection test on nasopharyngeal specimens for diagnosing SARS-CoV-2 infection","volume":"93","author":"Courtellemont","year":"2021","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.esmoop.2022.100403_bib68","article-title":"Performance evaluation of a lateral flow assays for nasopharyngeal antigen detection for SARS-CoV-2 diagnosis","volume":"35","author":"Pe\u00f1a-Rodr\u00edgez","year":"2021","journal-title":"J\u00a0Clin Lab Anal"},{"key":"10.1016\/j.esmoop.2022.100403_bib69","doi-asserted-by":"crossref","first-page":"104781","DOI":"10.1016\/j.jcv.2021.104781","article-title":"Diagnostic performance of CerTest and Panbio antigen rapid diagnostic tests to diagnose SARS-CoV-2 infection","volume":"137","author":"P\u00e9rez-Garc\u00eda","year":"2021","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.esmoop.2022.100403_bib70","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00083-21","article-title":"Performance and implementation evaluation of the Abbott BinaxNOW rapid antigen test in a high-throughput drive-through community testing site in Massachusetts","volume":"59","author":"Pollock","year":"2021","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.esmoop.2022.100403_bib71","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ijid.2021.02.052","article-title":"Comparative evaluation of four SARS-CoV-2 antigen tests in hospitalized patients","volume":"105","author":"Thommes","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.esmoop.2022.100403_bib72","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.cmi.2021.02.001","article-title":"Multicenter evaluation of the Panbio\u2122 COVID-19 rapid antigen-detection test for the diagnosis of SARS-CoV-2 infection","volume":"27","author":"Merino","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.esmoop.2022.100403_bib73","article-title":"Saliva viral load is a dynamic unifying correlate of COVID-19 severity and mortality","author":"Silva","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.esmoop.2022.100403_bib74","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1056\/NEJMc2016359","article-title":"Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2","volume":"383","author":"Wyllie","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100403_bib75","first-page":"1843","article-title":"Detection of SARS-CoV-2 in different types of clinical specimens","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.esmoop.2022.100403_bib76","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3390\/diagnostics11020363","article-title":"Diagnosis of SARS-Cov-2 infection by RT-PCR using specimens other than naso- and oropharyngeal swabs: a systematic review and meta-analysis","volume":"11","author":"Moreira","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.esmoop.2022.100403_bib77","doi-asserted-by":"crossref","first-page":"2001134","DOI":"10.2807\/1560-7917.ES.2021.26.10.2001134","article-title":"Towards a sensitive and accurate interpretation of molecular testing for SARS-CoV-2: a rapid review of 264 studies","volume":"26","author":"Stanoeva","year":"2021","journal-title":"Euro Surveill"},{"key":"10.1016\/j.esmoop.2022.100403_bib78","doi-asserted-by":"crossref","first-page":"E210","DOI":"10.1002\/ajh.25870","article-title":"Granulocyte-colony stimulating factor in COVID-19: is it stimulating more than just the bone marrow?","volume":"95","author":"Nawar","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.esmoop.2022.100403_bib79","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/cid\/ciab534","article-title":"The effect of neutropenia and filgrastim (G-CSF) in cancer patients with COVID-19 infection","volume":"74(4)","author":"Zhang","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.esmoop.2022.100403_bib80","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100403_bib81","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.3324\/haematol.2020.262634","article-title":"Hemostatic alterations in COVID-19","volume":"106","author":"Peyvandi","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.esmoop.2022.100403_bib82","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/cid\/ciaa1249","article-title":"Duration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infectivity: when is it safe to discontinue isolation?","volume":"72","author":"Rhee","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.esmoop.2022.100403_bib83","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s40121-020-00324-3","article-title":"A\u00a0systematic review of the clinical utility of cycle threshold values in the context of COVID-19","volume":"9","author":"Rao","year":"2020","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.esmoop.2022.100403_bib84","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1056\/NEJMc2031670","article-title":"Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer","volume":"383","author":"Aydillo","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100403_bib85","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1056\/NEJMc2031364","article-title":"Persistence and evolution of SARS-CoV-2 in an immunocompromised host","volume":"383","author":"Choi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100403_bib86","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1182\/blood.2020006288","article-title":"The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients","volume":"135","author":"Treon","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.esmoop.2022.100403_bib87","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1097\/HS9.0000000000000529","article-title":"EHA\/ESMO clinical practice gidelines for the management of malignant lymphoma: recommendations for the second phase of the COVID-19 pandemic","volume":"5","author":"Dreyling","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.esmoop.2022.100403_bib88","doi-asserted-by":"crossref","first-page":"e432","DOI":"10.1097\/HS9.0000000000000432","article-title":"How we manage patients with chronic lymphocytic leukemia during the SARS-CoV-2 Pandemic","volume":"4","author":"Rossi","year":"2020","journal-title":"Hemasphere"},{"key":"10.1016\/j.esmoop.2022.100403_bib89","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100403_bib90","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/s41375-020-0876-z","article-title":"Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)","volume":"34","author":"Terpos","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.esmoop.2022.100403_bib91","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European Myeloma Network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.esmoop.2022.100403_bib92","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100403_bib93","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41408-019-0187-7","article-title":"The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG)","volume":"9","author":"Kyriakou","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.esmoop.2022.100403_bib94","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S1470-2045(20)30559-3","article-title":"Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group","volume":"22","author":"Terpos","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100403_bib95","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.esmoop.2022.100403_bib96","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejca.2021.02.011","article-title":"Prolonged SARS-CoV-2 viral shedding in patients with solid tumours and associated factors","volume":"148","author":"Rogado","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2022.100403_bib97","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41408-020-00372-5","article-title":"Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality","volume":"10","author":"Martinez-Lopez","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.esmoop.2022.100403_bib98","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Group","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100403_bib99","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.esmoop.2022.100403_bib100","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.2019000241","article-title":"Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma","volume":"134","author":"Rosinol","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.esmoop.2022.100403_bib101","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100403_bib102","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100403_bib103","doi-asserted-by":"crossref","first-page":"101929","DOI":"10.1016\/j.ctrv.2019.101929","article-title":"Multiple myeloma: role of autologous transplantation","volume":"82","author":"Ntanasis-Stathopoulos","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2022.100403_bib104","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100403_bib105","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.15806","article-title":"Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study","volume":"185","author":"Yimer","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.esmoop.2022.100403_bib106","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/leu.2014.60","article-title":"Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma","volume":"28","author":"Dimopoulos","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.esmoop.2022.100403_bib107","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100403_bib108","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100403_bib109","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100403_bib110","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100403_bib111","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41375-020-01107-y","article-title":"High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib","volume":"35","author":"Barbui","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.esmoop.2022.100403_bib112","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/bjh.17890","article-title":"COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report","volume":"196","author":"Breccia","year":"2022","journal-title":"Br J Haematol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922000242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922000242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:26:53Z","timestamp":1761856013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922000242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":112,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S2059702922000242"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100403","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing hematological cancer patients during the COVID-19 pandemic: an\u00a0ESMO-EHA Interdisciplinary Expert Consensus","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100403","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100403"}}